Guidance
Our Guidance explains the laws and regulations governing the development, manufacturing, marketing, and supply of therapeutic goods in Australia.
We recently introduced new features to improve your experience using Guidance on our website.
Loading...
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
- (-) Biological medicines (22)
- (-) Prescription medicines (48)
- Advanced therapies (2)
- Advertising (33)
- Advisory bodies and committees (2)
- Artificial Intelligence (AI) (3)
- Assessed listed medicines (24)
- Australian Register of Therapeutic Goods (ARTG) (30)
- Blood and blood components (10)
- Breast implant hub (1)
- Clinical trials (5)
- Complementary medicines (30)
- Cosmetics (4)
- COVID-19 (9)
- Disinfectants/Sterilants (5)
- Fees and payments (3)
- Import and export (8)
- In Vitro Diagnostic medical devices (IVDs) (41)
- Labelling and packaging (27)
- Legislation (8)
- Listed medicines (25)
- Manufacturing (40)
- Medical devices safety (24)
- Medicinal cannabis hub (4)
- Medicine safety (8)
- Metal-on-metal hip replacement implants hub (1)
- Non-prescription medicines (49)
- Over the counter (OTC) medicines (36)
- Registered complementary medicines (16)
- Regulatory compliance (27)
- Safety (15)
- Scheduling (national classification system) (5)
- Shortages (3)
- Sunscreens (2)
- TGA conformity assessment certification (7)
- Therapeutic goods regulation (32)
- Unique Device Identification (UDI) hub (2)
- Vaping hub (4)
- Weight loss products (1)
Search
66 result(s) found, displaying 1 to 25
-
GuidanceGuidance on how to apply to register a biosimilar medicine on the Australian Register of Therapeutic Goods (ARTG) and ongoing sponsor responsibilities.
-
GuidanceGuidance for sponsors on the fees payable and timeframes for different types of prescription medicine applications.
-
GuidanceGuidance to assist sponsors and manufacturers comply with Therapeutic Goods (Microbiological standards for medicines) (TGO 100) Order 2018.
-
GuidanceGuidance on requirements relating to impurities in prescription medicines entered in the Australian Register of Therapeutic Goods (ARTG).
-
GuidanceGuidance to assist sponsors to understand the process for submitting a priority registration application.
-
GuidanceGuidance on bioavailability and/or bioequivalence aspects of medicines including information on biowaivers.
-
GuidanceGuidance on when and how to provide Product Information to us.
-
GuidanceGuidance on criteria and supporting documentation required for a medicine to be eligible for provisional determination.
-
GuidanceGuidance on the process for registering new medicines with new trade names that are 'clones' of currently registered prescription medicines
-
GuidanceGuidance on providing adventitious agent safety information in applications for medicines containing, or manufactured using, materials of animal or human origin.
-
GuidanceGuidance for sponsors and manufacturers of prescription medicines that contain, or are produced by, genetically modified organisms (GMOs).
-
GuidanceThis guidance helps sponsors understand the eligibility criteria and supporting documentation required for a medicine to be eligible for priority determination.
-
GuidanceGuidance on provisional registration process for prescription medicines with provisional determination.
-
GuidanceGuidance about how to make variations to Australian Register of Therapeutic Goods (ARTG) entries for prescription medicines.
-
GuidanceGuidance on TGO 109: Standards for Biologicals - General and Specific Requirements.
-
GuidanceGuidance on TGO 108: Requirements around the minimisation of transmission of communicable diseases for therapeutic goods containing biologicals and human cell or tissue (HCT).
-
GuidanceGuidance for industry organisations applying to add a medicine to the Australian Register of Therapeutic Goods (ARTG).
-
GuidanceGuidance about the types of notifications and variations for chemically derived (non-biological) prescription medicines.
-
GuidanceGuidance about application pathways and data requirements for new generic medicines, and variations to existing medicines.
-
GuidanceGuidance on the mandatory requirements for reporting current and anticipated reportable medicine shortages and discontinuations in Australia.
-
GuidanceThis guidance will help you understand our pharmacovigilance inspection program (PVIP).
-
GuidanceGuidance for sponsors about how to apply for orphan drug designation for a prescription medicine.
-
GuidanceGuidance explaining how the method of preparation influences classification and whether autologous HCTs are eligible for exemptions.
-
GuidanceGuidance for biological sponsors on the eligibility criteria and supporting documents required for priority determination applications
-
GuidanceGuidance on submitting the CPD for prescription medicines.